Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cancer|July 1, 1993
Single-agent carboplatinum for advanced seminoma. A phase II studyH J Schmoll, A Harstrick, C Bokemeyer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 6, 2013
DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breastR Souchon, M-L Sautter-Bihl, F Sedlmayer, et al.
International Journal of Cancer|December 22, 1999
Radiotherapy for stages I and IIA/B testicular seminomaM Bamberg, H Schmidberger, C Meisner, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 5, 2013
DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancerF Sedlmayer, M-L Sautter-Bihl, W Budach, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|October 30, 2012
When are breast cancer patients old enough for the quitclaim of local control?M L Sautter-Bihl, F Sedlmayer, W Budach, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 3, 2016
DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrencesWolfgang Harms, W Budach, J Dunst, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 19, 2014
DEGRO practical guidelines: radiotherapy of breast cancer III--radiotherapy of the lymphatic pathwaysM-L Sautter-Bihl, F Sedlmayer, W Budach, et al.
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trialE Heidemann, H Stoeger, R Souchon, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|October 29, 2000
[Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)]R Souchon, S Krege, H J Schmoll, et al.
Pageof 6